Találati lista | Tudóstér

001-es BibID:	BIBFORM080686
035-os BibID:	(Scopus)85065427841
Első szerző:	Bereczky Zsuzsanna (orvosi laboratóriumi diagnosztika szakorvos)
Cím:	Inherited thrombophilia and the risk of myocardial infarction : current evidence and uncertainties / Zsuzsanna Bereczky, László Balogh, Zsuzsa Bagoly
Dátum:	2019
ISSN:	0022-9032
Megjegyzések:	Atherothrombotic diseases (ATEs) and venous thromboembolism (VTE) have been traditionally considered to have a distinct pathogenesis. Today, a growing body of evidence on the pathophysiology of thrombus formation has convincingly proved that they share more mutual risk factors than previously recognized. It has been shown in a number of case?control studies that there is a significant risk for a subsequent cardiovascular disease after VTE, although this risk is low or at most moderate. In the past 2 decades, the role of each inherited risk factor for VTE in relation to ATE has been intensively studied. Unfortunately, a large body of contradictory findings has been published that hinders consensus and transformation of knowledge into clinical practice. Complicated gene?gene interactions, small sample sizes, heterogeneous genetic and environmental patient backgrounds, confounding factors, and varied methodological designs may have contributed to opposing findings. In the case of rare thrombophilias, conclusions must be summarized based on case reports or case series, as only few case?control and cohort studies are available. In this review we focus on available evidence and controversies regarding the relationship between the classic inherited VTE risk factors (factor V Leiden, prothrombin 20210A, deficiencies of antithrombin, protein C, and protein S) and the risk of myocardial infarction (MI). We conclude that the risk of MI in patients with common inherited thrombophilia is generally modest. However, in patients with deficiencies of antithrombin, protein C, or protein S, the risk of MI or other ATEs is not negligible. A personalized clinical approach is suggested when testing for inherited thrombophilia in a patient with MI.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk acute myocardial infarction actor V Leiden protein C protein S thrombophilia
Megjelenés:	Kardiologia Polska. - 77 : 4 (2019), p. 419-429. -
További szerzők:	Balogh László (1976-) (kardiológus) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:	NKFIH FK128582 egyéb NKFIH K120042 egyéb NKFIH K116228 egyéb GINOP-2.3.2.-15-2016-00043 egyéb GINOP-2.3.2.-15-2016-00039 egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM082985
035-os BibID:	(PMID)31808421
Első szerző:	Lóczi Linda
Cím:	Antiphospholipid syndrome and the risk of myocardial infarction : current evidence and uncertainties / Linda Lóczi, János Kappelmayer, Tünde Tarr, Zsuzsa Bagoly
Dátum:	2020
ISSN:	0022-9032
Megjegyzések:	Antiphospholipid syndrome (APS) encompasses a wide spectrum of disease manifestations that may prevail in the form of venous or arterial thrombosis or lead to pregnancy complications in the presence of persisting antiphospholipid antibodies (aPL). Unlike in the case of congenital thrombophilias, in which venous thromboses are more likely to occur as compared with arterial events, aPL may cause thrombosis in both types of vascular systems. Arterial thrombosis in APS is fairly common and often involve coronary or cerebral arteries leading to myocardial infarction (MI) or stroke. In this review, we summarize the complex pathomechanisms leading to aPL?associated thrombosis and list challenges during the laboratory detection of these antibodies. Specific features of MI in patients with APS are summarized based on a comprehensive literature search of available case reports. Preventive and treatment strategies are discussed based on the current recommendations and most recent evidence. We conclude that the risk of MI in patients with APS is considerable and MI may be the first manifestation of the disease. MI in APS shows specific clinical features including relatively young age at presentation, no sex dominance, often normal coronaries without the sign of atherosclerosis, high risk of recurrent thrombotic events. Treatment of acute MI in patients with APS is often challenging and adverse events, including stent thrombosis, are more frequent as compared with patients without APS. Preventive strategies in APS should be personalized and include strict management of additional cardiovascular risk factors and long?term anticoagulation with vitamin K antagonists. Current evidence does not support the use of direct oral anticoagulants in the management of patients with APS with arterial thrombosis due to the high risk of recurrent events.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Kardiologia Polska. - 78 : 1 (2020), p. 6-14. -
További szerzők:	Kappelmayer János (1960-) (laboratóriumi szakorvos) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:	FK128582 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: